Holen Sie sich die Stockscreener-App
4.27
0.23%
-0.01
Vorhandelsmarkt:
4.27
Schlusskurs vom Vortag:
$4.28
Offen:
$4.47
24-Stunden-Volumen:
249.64K
Relative Volume:
0.09
Marktkapitalisierung:
$12.19M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-7.97M
KGV:
-1.097
EPS:
-3.8923
Netto-Cashflow:
$-6.79M
1W Leistung:
-18.04%
1M Leistung:
+175.48%
6M Leistung:
+6.22%
1J Leistung:
-49.82%
1-Tages-Spanne:
$4.21
$4.58
1-Wochen-Bereich:
$3.85
$7.5392
52-Wochen-Spanne:
$1.3259
$21.00
Acurx Pharmaceuticals Inc Stock (ACXP) Company Profile
Firmenname
Acurx Pharmaceuticals Inc
Sektor
Branche
Telefon
917-533-1469
Adresse
259 LIBERTY AVENUE, STATEN ISLAND
Compare ACXP vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACXP
Acurx Pharmaceuticals Inc
|
4.27 | 12.19M | 0 | -7.97M | -6.79M | -3.8923 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Acurx Pharmaceuticals Inc Aktie (ACXP) Neueste Nachrichten
Acurx Pharmaceuticals Inc (ACXP) Q4 2025 Earnings Call Highlights: Financial Growth and ... By GuruFocus - Investing.com Canada
What's going on with Acurx Pharmaceuticals stock today? - MSN
Why is Acurx Pharmaceuticals stock falling Thursday? - MSN
Can Acurx Pharmaceuticals (ACXP) climb 226.3% to reach the level Wall Street analysts expect? - MSN
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Can Acurx Pharmaceuticals (ACXP) Surge by 226.3% to Meet the Target Set by Wall Street Analysts? - Bitget
Can Acurx Pharmaceuticals (ACXP) Rise by 226.3% to Meet the Target Set by Wall Street Experts? - Bitget
Can Acurx Pharmaceuticals (ACXP) Climb 226.3% to Reach the Level Wall Street Analysts Expect? - Yahoo Finance
ACXP Should I Buy - Intellectia AI
Acurx signals launch of pivotal recurrent CDI trial in H2 2026 while strengthening ibezapolstat pipeline - MSN
Is Acurx Pharmaceuticals (ACXP) outperforming other medical stocks this year? - MSN
Acurx Pharmaceuticals Drives Stock Surge with Major Clinical Developments - StocksToTrade
Is Acurx Pharmaceuticals (ACXP) Surpassing Other Healthcare Stocks in Performance This Year? - Bitget
Is Acurx Pharmaceuticals (ACXP) Outperforming Other Medical Stocks This Year? - Yahoo Finance
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Analysts Are Bullish on These Healthcare Stocks: Nuvalent (NUVL), Acurx Pharmaceuticals (ACXP) - The Globe and Mail
What's Going On With Acurx Pharmaceuticals Stock Today? - Sahm
Acurx Pharmaceuticals (ACXP) Gets a Buy from Alliance Global Partners - The Globe and Mail
Analysts Are Bullish on Top Healthcare Stocks: Acurx Pharmaceuticals (ACXP), BioLife Solutions (BLFS) - The Globe and Mail
Acurx Pharmaceuticals stock gains over 3% on new rCDI trial launch - Investing.com Canada
Acurx Pharmaceuticals (ACXP) Stock Rockets 218% as Phase 3 CDI Trial Gets Green Light - MEXC
Acurx Pharmaceuticals, Inc. (ACXP) Stock: Reduces Net Loss While Expanding Ibezapolstat Clinical Program - parameter.io
Acurx Pharmaceuticals Reports Full Year and Q4 Results, Provides Business Update - National Today
Acurx Pharmaceuticals (ACXP) Stock Explodes 218% on CDI Clinical Trial Breakthrough - MEXC
Acurx Pharma Stock Dips 9% Amid Market Volatility - timothysykes.com
Acurx Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
ACXP: Strong phase II results and new rCDI trial drive momentum amid improved financials - TradingView
Earnings call transcript: Acurx Pharmaceuticals Q4 2025 reveals cash boost and R&D progress - Investing.com
ACXP: Ibezapolstat progresses toward first-in-class status for rCDI, with strong results and new trials - TradingView
Acurx Pharmaceuticals (ACXP) Stock Soars 218% Following Phase 3 CDI Trial Approval - parameter.io
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Resigns with New to The Street for Long-Form Interviews, National TV Commercials, Earned Media, and Accredited Investor Events - Times Record News
Earnings Scheduled For March 13, 2026 - Benzinga
ACXP: Cash up, losses down, and ibezapolstat advances toward pivotal Phase 3 trials - TradingView
Acurx starts recurrent C. diff trial to treat and prevent - Stock Titan
Acurx Pharmaceuticals (ACXP) secures new US patent for DNA polymerase IIIC inhibitors - MSN
Why Petco Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket - Sahm
Why Is Acurx Pharmaceuticals Stock Falling Thursday? - Sahm
Pullback Watch: What are the risks of holding Acurx Pharmaceuticals Inc2026 Movers & Weekly Top Gainers Trade List - baoquankhu1.vn
Acurx Pharmaceuticals Stock (ACXP) Explodes 218% as New Trial Moves Forward on 96% Cure Rate - TipRanks
Acurx Pharmaceuticals 10-K: $0 Revenue, Net Loss $7.97M - TradingView
Acurx Pharmaceuticals (ACXP) highlights ibezapolstat CDI data and $1B market - Stock Titan
Acurx Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Why is Acurx Pharmaceuticals stock up over 105% today? - MSN
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Finanzdaten der Acurx Pharmaceuticals Inc-Aktie (ACXP)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):